ETFs see record number of funds shut down: ‘It’s a sign of health’

Exchange-traded products kept growing in 2016, both in popularity and in the money investors were willing to commit. But with growth comes growing pains, and the year featured one telling sign of the times: A record number of fund closures.

In all, 128 exchange-traded notes or funds shuttered during the year, a number that easily eclipsed the previous record of 102.

It’s not necessarily a bad sign, though. Industry watchers have been concerned that expansion has come too quickly and a shakeout of some sort probably is due.

“This isn’t a sign of weakness, it’s a sign of health,” Dave Nadig, ETF.com CEO, said in a report on the site. “It’s far better that funds are closed than that they sit around becoming untradeable zombies.”

The jump in closed funds may just be a sign of a maturing industry. After all, the total number of funds actually expanded during the year by a net 112 to 1,960, according to a count by industry tracker XTF. On top of that, total assets jumped to $2.56 trillion, a 20.4 percent increase.

State Street Global Advisors saw the most funds closed at 16, while BlackRock was second with 14 and ProShares was next with 11. BlackRock continues to be the industry leader with $983.1 billion under management, while Vanguard is next with $612.2 billion and State Street is third at $505.1 billion. Together, the big three firms control nearly 82 percent of all ETF assets.

Exchange-traded notes were particularly hard-hit in the purge, with 29 delistings and only 18 launches. ETNs are debt instruments from banks that, like ETFs, also track indexes. Deutsche Bank delisted two of its leveraged oil products this year.

Invest With An Edge keeps track of the industry’s health and added 25 funds to its “ETF Deathwatch” in December, while removing 12. In all, there are 464 exchange-traded products on the list, which includes 373 ETFs and 91 ETNs.

ETFs see record number of funds shut down: ‘It’s a sign of health’ - overview

Summary: Exchange-traded products kept growing in 2016, both in popularity and in the money investors were willing to commit. But with growth comes growing pains, and the year featured one telling sign of the times: A record number of fund closures.

Consider the life of a chef on the road. Even when they’re not doing “research” for an upcoming project—trips that are essentially designed for overeating and drinking—they’re still likely seeking the best of what got them into the industry in the first place: damn good food.

The proliferation of low-cost airlines flying out of the U.S. means that it’s now possible to hop to Europe for as low as half the price charged by major carriers, the New York Times writes. But there’s always a trade-off — and it pays to comparison-shop, according to the publication.

Featured Contributors

Chasing snake oil and fad gurus is harmless until your journey of personal discovery becomes a platform for prescribing therapies to complete strangers. Any reasonably diligent venture capital partner should be weighing the risks.

Shkreli — who famously insulted members of Congress earlier this year but refused to testify officially over his own decision to increase the price of a life-saving pill — is now hopping at the chance to defend generic drug manufacturer Mylan.
He may even have opened the door to testify before the House Committee on Oversight and Government Reform, where he previously cited his Fifth Amendment's right to avoid incriminating himself.
"Any chance i can come through this time and actually testify?" he tweeted Thursday in a post directed at the committee's Democrats.
All of this now paves an unlikely new friendship between Shkreli and Mylan CEO Heather Bresch.
Heather Bresch created about $15 billion in value for Mylan in the seven years since she stepped up as president of the company. A big part of that value add came from her talent for repackaging off-the-shelf drugs into bona fide blockbusters.

Donald Trump is talking about Hillary Clinton’s health, as are two doctors who havenever evaluated Clinton. They have apparently diagnosed her with all kinds of ailments using the long disproven Fox-Drudge equation.
This attention on Clinton has renewed some interest in the letter Donald Trump released last year from his personal physician.

Even as doctors enter a medical field with more paying patients under the Affordable Care Act and unprecedented numbers of job opportunities, 25 percent of “newly trained physicians” would still choose another field if they could, according to a new analysis.